Cart
0

Non-Alcoholic Steatohepatitis (NASH) Market Expected to Reach $21,478 Million,Globally, by 2025

 
 

quote high unmet needs and expected launch of strong pipeline drugs would play a major role in the growth of the NASH market. Furthermore, growth in prevalence of NASH and rise in demand for ideal NASH therapeutics are expected to boost the demand for NASH therapeutics in the coming years. quote

Pallavi Jaiswal
Senior Research Analyst, Healthcare Research at AMR

Get 20% Free Customization In This Report
Follow us on Social Media:       
 

According to a new report published by Allied Market Research, titled, Non-Alcoholic Steatohepatitis (NASH) Market, by Drug Type and Sales Channel: Global Opportunity Analysis and Industry Forecast, 20212025," the global non-alcoholic steatohepatitis (NASH) market was valued at $1,179 million in 2017, and is expected to reach $21,478 million by 2025, growing at a CAGR of 58.4% from 2021 to 2025.

Non-alcoholic steatohepatitis (NASH), is a common liver disease, often called as silent liver disease. It is asymptomatic until its later stages, and thus many patients are unaware of their condition. NASH is projected to lead the cause of liver transplantation in the U.S. in the coming years. Some major factors such as higher prevalence of NASH, expected launch of pipeline drugs, and higher number of unmet needs drive the growth of this market. However, poor diagnosis of NASH due to the lack of ideal diagnostic technologies limit the growth of the NASH market.

At present, there is no FDA-approved drug available in the market for the treatment of NASH. Lifestyle interventions are the first-line approach to manage patients with NASH. Based on drug type, the market is segmented into vitamin E & pioglitazone, ocaliva, elafibranor, and selonsertib & cenicriviroc. Vitamin E & pioglitazone segment contributes majorly due to effectiveness in a treatment of steatosis, inflammation, hepatocyte ballooning, and scarring in NASH patients.

Based on sales channel, the market is segmented into hospital pharmacy, online provider, and retail pharmacy. At present, the retail pharmacy segment is major revenue generator, and is estimated to show dominance during the forecast period due to the patient convenience and strong presence of retail pharmacies around the world. However, the online provider segment is projected to exhibit the fastest market growth due to rise in awareness of online pharmacies and increase in preference for online purchase of drugs over the traditional methods.

Key Findings of the Non-alcoholic Steatohepatitis (NASH) Market :

  • Based on drug type, the selonsertib & cenicriviroc segment is expected to exhibit the fastest market growth, is projected to grow at a CAGR of 73.7% from 2021 to 2025.
  • Based on sales channel, the retail pharmacy segment held more than half of the global market share in 2017 and is expected to remain dominant throughout the forecast period.
  • Based on sales channel, the online provider segment exhibited fastest growth and is anticipated to grow at a CAGR of 63.2% from 2021-2025.
  • Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 62.62% during the forecast period.

North America accounted approximately one half of the global market share in 2017 and is expected to remain dominant throughout the forecast period. Major factors that driving the market growth in North America are, early diagnosis of the disease, higher prevalence of disease, and strong presence of pipeline drugs. On the other hand, Asia-Pacific is expected to experience the highest CAGR of 62.62% during the forecast period primarily due to growth in prevalence of NASH along with the increase in prevalence of diabetes & obesity and rise in awareness of NASH among the patients. Furthermore, growth in number of R&D activities, development in diagnostic technologies, and increase in healthcare spending is expected to drive the NASH market in Asia-Pacific region.

Need More Information

pr-det-talk Talk to David (Europe)

pr-det-talk Talk to Sona Padman (Americas)

5933 NE Win Sivers Drive #205,
Portland, OR 97220 United States

pr-det-phone Toll Free: +1-800-792-5285

pr-det-phone UK: +44-845-528-1300

pr-det-phone Hong Kong: +852-301-84916

pr-det-phone India (Pune): +91 2066346060

pr-det-phone Fax: +1⟨855⟩ 550-5975

pr-det-phone help@alliedmarketresearch.com

 

For Media Inquiries, Please Contact

Abhinav Rautela
Communications Officer
Allied Market Research
Contact Toll Free: +1-800-792-5285
Drop us an email at
mediacommunications@alliedanalytics.com

 
 

First time buyer?
Check offers and discount on this report
To get this report

 
Click Here
 
 

quote Non-Alcoholic Steatohepatitis (NASH) Market by Drug Type (Vitamin E & Pioglitazone, Ocaliva, Elafibranor, and Selonsertib & Cenicriviroc), and Sales Channel (Hospital Pharmacy, Online Provider, and Retail Pharmacy) - Global Opportunity Analysis and Industry Forecast, 2021-2025 quote

View Report
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

Targeted Market View

Targeted market view to eliminate redundant information to provide valued information and save time of the reader

 

Featured Readings

 
rep-img

Published Date Dec 2018

Robotic Lawn Mower Market

Download Sample
 

Get Fresh content delivered

Get insights on topics that matter to your business. Stay updated on the area that interest you.

 
Get Industry Data Alerts